About US
Contact us
-
FDA probes long-acting Zyprexa safety after 2 patients dieTwo patients have died unexpectedly after their Zyprexa Relprevv injections, and the FDA is now investigating. The agency says the patients died three to four days after receiving "an appropriate dose2013/6/18
-
Elan goes on the block in the final hour of takeover fightElanis officially up for sale. Seeking to dodge a hostile takeover bid fromRoyalty Pharma, the Irish company said Friday morning that it has begun a formal sales process,Reutersreports, and invited Ro2013/6/17
-
Wockhardt gets kicked in the gut againThere is more financially painful news for India'sWockhardt. India has banned the sale of painkiller dextropropoxyphene, and Wockhardt's branded version, Proxyvon, made up about 4% of its sales. That2013/6/17
-
Credit Suisse says Pfizer patent win will discourage 'at-risk' launchesWill Pfizer's ($PFE) big patent win against Teva Pharmaceutical Industries ($TEVA) and India'sSun PharmaonProtonixdiscourage more "at-risk" drug launches of generics in the U.S.? Credit Suisse thinks2013/6/14
-
UPDATED: GSK probes sales tactics in China days after firing R&D chief thereSales scandals are breaking out around the world for Big Pharma. Novartis ($NVS) acknowledged this week it had terminated some sales execs in India as it probes unethical practices there, and now Glax2013/6/14
-
Sales upside for Sanofi's Fluzone Quadrivalent looks strongThe FDA two days ago gave its approval to Sanofi's ($SNY)Fluzone Quadrivalent, a 4-in-1influenzavaccine, and now the estimates on the revenue upside are starting to roll in. GlobalData says they look2013/6/13
-
PDL, Roche duke it out over royalties for Avastin, HerceptinEven friends have disputes over money sometimes. That's what's happening withPDL BioPharmaand Roche's ($RHHBY)Genentech: PDL wants to take Genentech to arbitration for underpaying royalties, theAPrepo2013/6/13
-
Royalty tries to seal the deal with bid for Elan that could be worth $8BElan ($ELN) and Royalty Pharmahave been in a rapid back-and-forth of one-upmanship to win the hearts and votes of Elan shareholders. But the latest offer from Royalty may turn the tide. Royalty wants2013/6/9
-
UPDATED: FDA advisers vote for looser reins on GlaxoSmithKline's AvandiaIt took multiple tries and a vote tallied on paper to make sure everything was correct, but finally, we have a verdict. After two days of hearings, on Thursday an advisory panel recommended the FDA ke2013/6/9
-
Sanofi uses multi-pronged strategy to defend its place in diabetes marketLantusis the best-selling diabetes drug in the world right now, hitting $6.674 billion last year. It is also the top-selling drug for Sanofi ($SNY). But the French drugmaker is not letting all of that2013/6/8